Olsalazine Versus Sulfasalazine in Mild to Moderate Childhood Ulcerative Colitis
George D. Ferry(Baylor College of Medicine), Bobbette A. Jones(Texas Children's Hospital), Eric Hassall(University of British Columbia), Robert M. Issenman(Texas Children's Hospital), Barbara S. Kirschner(Comer Children's Hospital), William J. Byrne(Texas Children's Hospital), Anne M. Griffiths(University of Toronto), Harland S. Winter(Massachusetts General Hospital), Danièl Thomas(Unknown), Richard J. Grand(Boston Children's Hospital), Jay A. Perman(University of Louisville), Frederic Daum(Texas Children's Hospital), John B. Watkins(Children's Hospital of Wisconsin), James E. Heubi(Cincinnati Children's Hospital Medical Center), Martin H. Ulshen(Duke Medical Center), John Vanderhoof(Texas Children's Hospital), Joyce D. Gryboski(Loma Linda University), Stephen C. Fiedorek(Texas Children's Hospital)
Cited by 13
Related Papers
The Treatment-Naive Microbiome in New-Onset Crohn’s Disease
|Cell Host & Microbe|2014|3.3k
A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene
|Science|2006|3k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k